Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.

Autor: Váraljai R; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany., Zimmer L; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany., Al-Matary Y; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany., Kaptein P; Division of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands., Albrecht LJ; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany., Shannan B; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany., Brase JC; Novartis Pharma AG, Basel, Switzerland., Gusenleitner D; Novartis Institutes for BioMedical Research, Inc., Cambridge, MA, USA., Amaral T; Department of Dermatology, University Hospital of Tübingen, Tübingen, Germany., Wyss N; Institute of Immunobiology, Kantonsspital St. Gallen, Switzerland, Switzerland., Utikal J; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karls University of Heidelberg, Mannheim, Germany.; DKFZ Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany., Flatz L; Department of Dermatology, University Hospital of Tübingen, Tübingen, Germany.; Institute of Immunobiology, Kantonsspital St. Gallen, Switzerland, Switzerland., Rambow F; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.; Department of Applied Computational Cancer Research, Institute for AI in Medicine (IKIM), University Hospital Essen, Essen, Germany., Reinhardt HC; Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.; Center for Medical Biotechnology (ZMB), University of Duisburg-Essen, Essen, Germany., Dick J; Department of Immunodynamics, Institute of Experimental Immunology and Imaging, University Hospital Essen, Essen, Germany., Engel DR; Department of Immunodynamics, Institute of Experimental Immunology and Imaging, University Hospital Essen, Essen, Germany., Horn S; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.; Rudolf Schönheimer Institute of Biochemistry, Medical Faculty, University of Leipzig, Leipzig, Germany., Ugurel S; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany., Sondermann W; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany., Livingstone E; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany., Sucker A; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany., Paschen A; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.; Center for Medical Biotechnology (ZMB), University of Duisburg-Essen, Essen, Germany., Zhao F; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany., Placke JM; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany., Klose JM; Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Fendler WP; Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Thommen DS; Division of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands., Helfrich I; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.; Department of Dermatology and Allergology, Ludwig Maximilian University Munich, Munich, Germany., Schadendorf D; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.; Center for Medical Biotechnology (ZMB), University of Duisburg-Essen, Essen, Germany.; NCT West, Campus Essen and University Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany., Roesch A; Department of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany. alexander.roesch@uk-essen.de.; Center for Medical Biotechnology (ZMB), University of Duisburg-Essen, Essen, Germany. alexander.roesch@uk-essen.de.

Publikováno v: Nature cancer [Nat Cancer] 2023 Sep; Vol. 4 (9), pp. 1395.